Gene Silencing of the Mitochondrial Adaptor p66 Shc Suppresses Vascular Hyperglycemic Memory in Diabetes
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Rationale: Hyperglycemic memory may explain why intensive glucose control has failed to improve cardiovascular outcomes in patients with diabetes. Indeed, hyperglycemia promotes vascular dysfunction even after glucose normalization. However, the molecular mechanisms of this phenomenon remain to be elucidated. Objective: The present study investigated the role of mitochondrial adaptor p66 Shc in this setting. Methods and Results: In human aortic endothelial cells (HAECs) exposed to high glucose and aortas of diabetic mice, activation of p66 Shc by protein kinase C βII (PKCβII) persisted after returning to normoglycemia. Persistent p66 Shc upregulation and mitochondrial translocation were associated with continued reactive oxygen species (ROS) production, reduced nitric oxide bioavailability, and apoptosis. We show that p66 Shc gene overexpression was epigenetically regulated by promoter CpG hypomethylation and general control nonderepressible 5–induced histone 3 acetylation. Furthermore, p66 Shc -derived ROS production maintained PKCβII upregulation and PKCβII-dependent inhibitory phosphorylation of endothelial nitric oxide synthase at Thr-495, leading to a detrimental vicious cycle despite restoration of normoglycemia. Moreover, p66 Shc activation accounted for the persistent elevation of the advanced glycated end product precursor methylglyoxal. In vitro and in vivo gene silencing of p66 Shc , performed at the time of glucose normalization, blunted ROS production, restored endothelium-dependent vasorelaxation, and attenuated apoptosis by limiting cytochrome c release, caspase 3 activity, and cleavage of poly (ADP-ribose) polymerase. Conclusions: p66 Shc is the key effector driving vascular hyperglycemic memory in diabetes. Our study provides molecular insights for the progression of diabetic vascular complications despite glycemic control and may help to define novel therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationReactive Oxygen Species in Metabolic and Inflammatory Signaling
Forrester, S. J., Kikuchi, D. S., Hernandes, M. S., Xu, Q., & Griendling, K. K. (2018) · Circulation Research · doi:10.1161/circresaha.117.311401 · Cited by 2,081
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Reperfusion injury and reactive oxygen species: The evolution of a concept
Granger, D. N., & Kvietys, P. R. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.020 · Cited by 1,484
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
Paneni, F., Beckman, J. A., Creager, M. A., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht149 · Cited by 1,401
Self-citationKalogeris, T., Bao, Y., & Korthuis, R. J. (2014) · Redox Biology · doi:10.1016/j.redox.2014.05.006 · Cited by 716
Reactive oxygen species (ROS) in macrophage activation and function in diabetes
Rendra, E., Riabov, V., Mossel, D. M., Sevastyanova, T., Harmsen, M. C., & Kzhyshkowska, J. (2019) · Immunobiology · doi:10.1016/j.imbio.2018.11.010 · Cited by 636
Eelen, G., de Zeeuw, P., Treps, L., Harjes, U., Wong, B. W., & Carmeliet, P. (2018) · Physiological Reviews · doi:10.1152/physrev.00001.2017 · Cited by 572
Diabetes, oxidative stress and therapeutic strategies
Rochette, L., Zeller, M., Cottin, Y., & Vergely, C. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.05.017 · Cited by 530
Mitochondria and Endothelial Function
Kluge, M. A., Fetterman, J. L., & Vita, J. A. (2013) · Circulation Research · doi:10.1161/circresaha.111.300233 · Cited by 508
“Furthermore, p66Shc is activated via phosphorylation by protein kinase CβII in the setting of high glucose and contributes to the development of diabetic endothelial dysfunction.(68,69) Thus, p66Shc transduces environmental signals into ROS that signal apoptosis and other cellular responses.”
BackgroundMitochondria, endothelial cell function, and vascular diseases
Tang, X., Luo, Y.-X., Chen, H.-Z., & Liu, D.-P. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00175 · Cited by 345
Scioli, M. G., Storti, G., D’Amico, F., Rodríguez Guzmán, R., Centofanti, F., Doldo, E., Céspedes Miranda, E. M., & Orlandi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061995 · Cited by 281
“Its overexpression was reported to be epigenetically regulated by promoter CpG hypomethylation and nonderepressible, 5-induced, histone three acetylation [48].”
BackgroundInfluentialLysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease
Li, P., Ge, J., & Li, H. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0235-9 · Cited by 269
The epigenetic landscape related to reactive oxygen species formation in the cardiovascular system
Kietzmann, T., Petry, A., Shvetsova, A., Gerhold, J. M., & Görlach, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13792 · Cited by 253
“In a model of increased ROS due to removal of 2-mercaptoethanol, 8-oxodG formation resulted in activation of the transcription factor Tbx5 and enhanced differentiation of murine embryonic stem cells to cardiomyocytes (Park et al., 2016).”
BackgroundEpigenetic Changes in Diabetes and Cardiovascular Risk
Keating, S. T., Plutzky, J., & El-Osta, A. (2016) · Circulation Research · doi:10.1161/circresaha.116.306819 · Cited by 139
SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory
Paneni, F., Volpe, M., Lüscher, T. F., & Cosentino, F. (2013) · Diabetes · doi:10.2337/db12-1648 · Cited by 118
Self-citationSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
Epigenetics in diabetic nephropathy, immunity and metabolism
Keating, S. T., van Diepen, J. A., Riksen, N. P., & El-Osta, A. (2018) · Diabetologia · doi:10.1007/s00125-017-4490-1 · Cited by 82
Epigenetic Signatures and Vascular Risk in Type 2 Diabetes: A Clinical Perspective
Paneni, F., Costantino, S., Volpe, M., Lüscher, T. F., & Cosentino, F. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.003 · Cited by 70
Self-citationShahzad, K., Gadi, I., Nazir, S., Al-Dabet, M. M., Kohli, S., Bock, F., Breitenstein, L., Ranjan, S., Fuchs, T., Halloul, Z., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0108-5 · Cited by 40
p66Shc-induced redox changes drive endothelial insulin resistance
Paneni, F., Costantino, S., & Cosentino, F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.07.027 · Cited by 38
“delivery occurs in vascular endothelial cells [12].”
BackgroundMethodSelf-citation
Metadata
- Authors
- Paneni, F., Mocharla, P., Akhmedov, A., Costantino, S., Osto, E., Volpe, M., Lüscher, T. F., & Cosentino, F.
- Venue
- Circulation Research
- Published
- 2012-07-20
- Volume
- 111
- Issue
- 3
- Pages
- 278-289
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2108184274
- Cited by
- 256
- References
- 58
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.